Helsinki-based CurifyLabs has closed a $14M Series A funding round, co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd) and existing investors, including Lifeline Ventures.
The team also expressed its gratitude to the many US customers and employees who believe in what the company is building.
CurifyLabs says that pharmacies across 21 US states and Europe currently use its Compounding System Solution to compound and dispense thousands of personalised doses every day. The solution combines proprietary software, GMP-manufactured excipient bases and 3D printing to deliver tailored medications with greater precision and speed than manual compounding.
The funding will help the company expand its US operations, strengthen its supply chain, enhance customer support and accelerate product innovation.
CurifyLabs has built something rare — technology that combines clinical rigour with the speed and precision that busy pharmacy teams depend on.
Morten E. Iversen, Partner at Sandwater
What sets the best founders apart is their ability to combine scientific depth with real-world execution. The CurifyLabs team has done exactly that.
Daniel Karsberg, Partner at HealthCap
CurifyLabs is the kind of company we want to support — innovative, globally ambitious, and built on deep scientific expertise.
Joni Karsikas, Investment Director at Tesi
CurifyLabs is a healthtech company developing solutions for the automated compounding of personalised medicines in pharmacies and hospitals.
The company was founded in 2021 by Charlotta Topelius and Niklas Sandler.
